ICU dialysis: which dose of blood thinner works best?
NCT ID NCT07469072
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two starting doses (20 mg/h vs. 50 mg/h) of the blood thinner nafamostat in ICU patients receiving continuous kidney dialysis. The goal is to see which dose keeps the dialysis filter from clotting longer while avoiding dangerous bleeding. About 92 adults will be randomly assigned to one of the two doses, and doctors will track how long each filter lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nafamostat Mesilate (a blood-thinning drug)
What this could lead to
If it works, this could help doctors choose the best dose of nafamostat to keep dialysis filters working longer and reduce bleeding risks in ICU patients.
What could go wrong
This is a small, early-phase trial (92 people) at one hospital, so results may not apply to all patients. The drug can cause bleeding, and the higher dose may not be safer or more effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Critical Care Medicine of Zhujiang Hospital,Southern Medical University
RECRUITINGGuangzhou, Guangdong, 510282, China
Contact Phone: •••-•••-•••• Email: •••••@•••••